$DCTH
Delcath Systems Inc

2016 Q4 Form 10-Q Financial Statement

#000156459016028959 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q3
Revenue $676.0K $400.0K
YoY Change 53.64% 81.82%
Cost Of Revenue $180.0K $90.00K
YoY Change 80.0% 80.0%
Gross Profit $500.0K $310.0K
YoY Change 47.06% 82.35%
Gross Profit Margin 73.96% 77.5%
Selling, General & Admin $2.410M $2.280M
YoY Change 10.05% -49.78%
% of Gross Profit 482.0% 735.48%
Research & Development $2.470M $1.680M
YoY Change 4.22% 147.06%
% of Gross Profit 494.0% 541.94%
Depreciation & Amortization $80.00K $100.0K
YoY Change -33.33% -50.0%
% of Gross Profit 16.0% 32.26%
Operating Expenses $4.882M $3.960M
YoY Change 6.83% -24.14%
Operating Profit -$4.383M -$3.650M
YoY Change 3.64% -27.78%
Interest Expense $10.21M -$14.00K
YoY Change -1315.48% -102.69%
% of Operating Profit
Other Income/Expense, Net -$14.31M -$11.00K
YoY Change 71450.0% -63.33%
Pretax Income -$8.490M -$2.420M
YoY Change 66.8% -46.93%
Income Tax
% Of Pretax Income
Net Earnings -$8.486M -$2.422M
YoY Change 66.56% -46.86%
Net Earnings / Revenue -1255.33% -605.5%
Basic Earnings Per Share -$1.292K
Diluted Earnings Per Share -$446900B -$240300B
COMMON SHARES
Basic Shares Outstanding 2.197M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.410M $16.67M
YoY Change -65.03% -28.52%
Cash & Equivalents $4.409M $16.67M
Short-Term Investments
Other Short-Term Assets $28.68M $660.0K
YoY Change 2887.5% 264.64%
Inventory $660.0K $400.0K
Prepaid Expenses
Receivables $403.0K $430.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $34.16M $18.17M
YoY Change 133.93% -26.59%
LONG-TERM ASSETS
Property, Plant & Equipment $1.083M $1.400M
YoY Change -4.33% -33.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.083M $1.400M
YoY Change -4.33% -33.96%
TOTAL ASSETS
Total Short-Term Assets $34.16M $18.17M
Total Long-Term Assets $1.083M $1.400M
Total Assets $35.24M $19.57M
YoY Change 123.98% -27.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $594.0K $220.0K
YoY Change 109.15% 100.0%
Accrued Expenses $3.407M $1.990M
YoY Change 51.89% -54.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.34M
YoY Change
Total Short-Term Liabilities $36.10M $5.180M
YoY Change 471.85% 1.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $604.0K $870.0K
YoY Change -26.34% -20.18%
Total Long-Term Liabilities $604.0K $870.0K
YoY Change -26.34% -20.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.10M $5.180M
Total Long-Term Liabilities $604.0K $870.0K
Total Liabilities $36.73M $6.050M
YoY Change 414.99% -2.1%
SHAREHOLDERS EQUITY
Retained Earnings -$279.2M
YoY Change 6.88%
Common Stock $0.00
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $51.00K
YoY Change 0.0%
Treasury Stock Shares $1.00
Shareholders Equity -$1.490M $13.52M
YoY Change
Total Liabilities & Shareholders Equity $35.24M $19.57M
YoY Change 123.98% -27.17%

Cashflow Statement

Concept 2016 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$8.486M -$2.422M
YoY Change 66.56% -46.86%
Depreciation, Depletion And Amortization $80.00K $100.0K
YoY Change -33.33% -50.0%
Cash From Operating Activities -$3.610M -$3.230M
YoY Change -14.66% -18.02%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$40.00K
YoY Change -75.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$20.00K -$40.00K
YoY Change -114.29% -300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.470M 6.010M
YoY Change -44800.0% -20133.33%
NET CHANGE
Cash From Operating Activities -3.610M -3.230M
Cash From Investing Activities -20.00K -40.00K
Cash From Financing Activities 4.470M 6.010M
Net Change In Cash 840.0K 2.740M
YoY Change -120.49% -169.37%
FREE CASH FLOW
Cash From Operating Activities -$3.610M -$3.230M
Capital Expenditures -$10.00K -$40.00K
Free Cash Flow -$3.600M -$3.190M
YoY Change -14.08% -19.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2016Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
489000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5975000
us-gaap Operating Expenses
OperatingExpenses
13000000
dei Entity Registrant Name
EntityRegistrantName
DELCATH SYSTEMS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0000872912
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4112000
us-gaap Operating Expenses
OperatingExpenses
11930000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12057000
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2197431
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Trading Symbol
TradingSymbol
DCTH
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12607000
CY2015Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14601000
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
6550000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0
CY2016Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
122000
CY2016Q3 us-gaap Depreciation
Depreciation
100000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2426000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9497000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
us-gaap Net Income Loss
NetIncomeLoss
-9611000
us-gaap Net Income Loss
NetIncomeLoss
-9485000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2422000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4963000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1007000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-14000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6584000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-39000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1005000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9623000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3785000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6312000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1316000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9171000
CY2015Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1308000
us-gaap Cost Of Revenue
CostOfRevenue
373000
us-gaap Cost Of Revenue
CostOfRevenue
360000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
255000
us-gaap Gross Profit
GrossProfit
943000
us-gaap Gross Profit
GrossProfit
948000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7025000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7818000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10982000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1414000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.38
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.75
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1521927
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1233086
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1486986
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
893819
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
138000
us-gaap Restricted Stock Expense
RestrictedStockExpense
228000
us-gaap Restricted Stock Expense
RestrictedStockExpense
189000
us-gaap Depreciation
Depreciation
232000
us-gaap Depreciation
Depreciation
504000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
dcth Deferred Revenues
DeferredRevenues
31000
dcth Deferred Revenues
DeferredRevenues
0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6567000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-610000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-306000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
94000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
135000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-190000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7487866
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
62000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
312000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2056000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-155000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-165000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10597000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12188000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
129000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8674000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2940000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
123000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
1087000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1332000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-127000
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-29200000
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
31436000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
704000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8674000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
71000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-162000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8918000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3803000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20469000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16666000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
28133000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4247000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
245000
CY2015Q3 us-gaap Depreciation
Depreciation
100000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
928000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
692000
CY2016Q3 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
782000
CY2015Q4 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
219000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
234000
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:4.54%;">Deferred Revenue</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue on the accompanying condensed consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. </p></div>
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
220000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
391000
CY2016Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
209000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock.
CY2016Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
dcth Effective Date Of Reverse Stock Split
EffectiveDateOfReverseStockSplit
2016-07-21
CY2016Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
313000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
360000
CY2016Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
171000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
251000
CY2016Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
116000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
146000
CY2016Q3 us-gaap Prepaid Insurance
PrepaidInsurance
85000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
625000
CY2015Q4 dcth Kits For Clinical Use
KitsForClinicalUse
162000
CY2016Q3 us-gaap Security Deposit
SecurityDeposit
49000
CY2015Q4 us-gaap Security Deposit
SecurityDeposit
74000
CY2016Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
176000
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
99000
CY2016Q3 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2015Q4 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2013Q4 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
7500000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4893000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4638000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3752000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3506000
CY2013Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6900000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
153750
CY2015Q1 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
2600000
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2500000
CY2015Q3 us-gaap Partners Capital Account Units Sale Of Units
PartnersCapitalAccountUnitsSaleOfUnits
600000
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
600000
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6000000
dcth Number Of Inputs Used For Valuation Of Warrants
NumberOfInputsUsedForValuationOfWarrants
6
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3785000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-9171000
CY2016Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
22502000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
548000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
721000
CY2016Q3 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2015Q4 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2013Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
81875

Files In Submission

Name View Source Status
0001564590-16-028959-index-headers.html Edgar Link pending
0001564590-16-028959-index.html Edgar Link pending
0001564590-16-028959.txt Edgar Link pending
0001564590-16-028959-xbrl.zip Edgar Link pending
dcth-10q_20160930.htm Edgar Link pending
dcth-20160930.xml Edgar Link completed
dcth-20160930.xsd Edgar Link pending
dcth-20160930_cal.xml Edgar Link unprocessable
dcth-20160930_def.xml Edgar Link unprocessable
dcth-20160930_lab.xml Edgar Link unprocessable
dcth-20160930_pre.xml Edgar Link unprocessable
dcth-ex311_7.htm Edgar Link pending
dcth-ex312_9.htm Edgar Link pending
dcth-ex321_8.htm Edgar Link pending
dcth-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending